Clene Inc.
$ 5.89
-5.76%
29 Dec - close price
- Market Cap 64,587,000 USD
- Current Price $ 5.89
- High / Low $ 6.23 / 5.70
- Stock P/E N/A
- Book Value -1.21
- EPS -3.44
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -17.38 %
- 52 Week High 13.50
- 52 Week Low 2.28
About
Clene Inc. is an innovative clinical-stage pharmaceutical company located in Salt Lake City, Utah, focused on advancing clean-surface nanotechnology (CSN) therapies to address neurodegenerative diseases and other critical health issues. The company is actively engaged in rigorous clinical trials to support the regulatory approval of its diverse and promising product pipeline, aiming to establish itself as a frontrunner in the biopharmaceutical industry. With a robust scientific foundation and a strategic vision geared towards transformative healthcare solutions, Clene presents a compelling growth opportunity for institutional investors interested in impactful advancements in medicine.
Analyst Target Price
$31.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-14 | 2025-05-06 | 2025-03-11 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-07 | 2023-08-14 | 2023-05-12 | 2023-03-13 |
| Reported EPS | -0.6084 | -0.78 | -0.4995 | -1.3646 | -1.1074 | -1.06 | -0.09 | -0.06 | -0.02 | -0.29 | -0.15 | -0.01 |
| Estimated EPS | -0.5633 | -0.07 | -0.784 | -0.878 | -1.32 | -1.49 | -0.08 | -0.07 | -0.09 | -0.12 | -0.14 | -0.12 |
| Surprise | -0.0451 | -0.71 | 0.2845 | -0.4866 | 0.2126 | 0.43 | -0.01 | 0.01 | 0.07 | -0.17 | -0.01 | 0.11 |
| Surprise Percentage | -8.0064% | -1014.2857% | 36.2883% | -55.4214% | 16.1061% | 28.8591% | -12.5% | 14.2857% | 77.7778% | -141.6667% | -7.1429% | 91.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLNN
2025-12-29 14:10:05
Short interest in Clene Inc. (NASDAQ:CLNN) surged by 47.4% to 576,736 shares as of December 15th, representing approximately 8.6% of the stock and a days-to-cover ratio of 1.2. Despite this increase in short interest and significant insider selling amounting to 267,744 shares in the last quarter, analysts are largely bullish with a "Moderate Buy" rating and a consensus price target of $32.60. Clene is a clinical-stage biopharmaceutical company focused on neurodegenerative disorders, with its lead candidate CNM-Au8 undergoing trials for ALS, Parkinson's, and MS.
2025-12-23 22:10:45
Major shareholder Chidozie Ugwumba sold 5,582 shares of Clene (NASDAQ:CLNN) stock on Friday, December 19th, valued at $36,003.90. This sale is part of a larger series of transactions in December, totaling 136,298 shares and reducing his ownership by 1.42%. Despite the insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $32.60 for Clene shares.
2025-12-23 22:10:45
Chidozie Ugwumba, a significant shareholder in Clene Inc. (NASDAQ:CLNN), recently sold 4,367 shares of the company's stock for $28,560.18, reducing his holdings by 1.13% to 383,201 shares. This sale is part of a pattern of insider selling throughout December, even as analysts maintain a "Moderate Buy" rating for the stock despite its current negative EPS and mixed financial sentiment. Clene Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle therapies for neurodegenerative disorders.
2025-12-21 16:34:00
An insider at Clene Inc. (NASDAQ:CLNN) recently sold US$1.7m worth of shares, reducing their holding by 40%. While this was a substantial sale, it occurred above the current share price. The article notes that insider ownership is relatively low at 14% and there have been no insider purchases in the last year, leading to a cautious outlook on the stock.
2025-12-21 14:09:41
An insider at Clene Inc. recently sold US$1.7m worth of stock, reducing their total holding by 40%. While this was a significant sale, it occurred at a price well above the current market value. Insiders own 14% of Clene shares, and there have been no insider purchases in the last year, which may not inspire confidence in the stock.
2025-12-19 03:09:10
A 10% owner of Clene Inc. (NASDAQ: CLNN), Chidozie Ugwumba, disclosed a series of open-market stock sales of common stock in December 2025 through Symbiosis II, LLC. The transactions, coded "S" on a Form 4 SEC filing, occurred between December 3 and December 18, 2025, with share prices ranging from $5.70 to $7.86. Following these sales, the beneficial ownership of Clene common stock by Symbiosis II, LLC stands at 393,150 shares as of December 18, 2025.
